FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: The FDA's approval of Casgevy for young children with sickle cell disease and beta thalassemia will directly impact North Carolina families, given the state's significant sickle cell disease patient population, particularly in communities with higher genetic predisposition.

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).